CY1114330T1 - Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου - Google Patents

Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου

Info

Publication number
CY1114330T1
CY1114330T1 CY20131100584T CY131100584T CY1114330T1 CY 1114330 T1 CY1114330 T1 CY 1114330T1 CY 20131100584 T CY20131100584 T CY 20131100584T CY 131100584 T CY131100584 T CY 131100584T CY 1114330 T1 CY1114330 T1 CY 1114330T1
Authority
CY
Cyprus
Prior art keywords
ser
insulin
amino acid
growth factor
medical uses
Prior art date
Application number
CY20131100584T
Other languages
English (en)
Inventor
Teruo Nishida
Makoto Inui
M Nakamura
Original Assignee
Santen Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd filed Critical Santen Pharmaceutical Co., Ltd
Publication of CY1114330T1 publication Critical patent/CY1114330T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Είναι ένα αντικείμενο της εφεύρεσης να εξετάσει την ελαχίστη μονάδα επίδειξης δραστικότητας του παράγοντα-Ι ανάπτυξης που ομοιάζει με ινσουλίνη και να ανακαλύψει μια φαρμακευτική χρήση αυτού στα πεδία οφθαλμολογίας και δερματολογίας. Μια κοινή χορήγηση ενός πεπτιδίου που περιέχει την αλληλουχία αμινοξέος που αντιπροσωπεύεται από Ser-Ser-Ser-Αrg ως την ελαχίστη μονάδα της επίδειξης δραστικότητας του παράγοντα-Ι ανάπτυξης που ομοιάζει με ινσουλίνη και ενός πεπτιδίου που περιέχει την αλληλουχία αμινοξέος που αντιπροσωπεύεται από Phe-Gly-Leu-Μet-ΝΗ2 είναι αποτελεσματική για θεραπεία διαταραχών του κερατοειδούς και μπορεί να προάγει σημαντικά την επούλωση δερματικών τραυμάτων.
CY20131100584T 2001-12-03 2013-07-10 Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου CY1114330T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001368103 2001-12-03
EP02786015.4A EP1462455B1 (en) 2001-12-03 2002-12-03 Ser-Ser-Ser-Arg peptide and medicinal uses thereof

Publications (1)

Publication Number Publication Date
CY1114330T1 true CY1114330T1 (el) 2016-08-31

Family

ID=19177744

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100584T CY1114330T1 (el) 2001-12-03 2013-07-10 Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου

Country Status (13)

Country Link
US (3) US7232881B2 (el)
EP (2) EP2172474B1 (el)
JP (1) JP4310588B2 (el)
KR (2) KR100993233B1 (el)
CN (1) CN1263770C (el)
CA (1) CA2469134C (el)
CY (1) CY1114330T1 (el)
DK (1) DK1462455T3 (el)
ES (1) ES2422081T3 (el)
PT (1) PT1462455E (el)
SI (1) SI1462455T1 (el)
TW (1) TWI305778B (el)
WO (1) WO2003048192A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006143601A (ja) * 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
US20090169491A1 (en) * 2006-03-06 2009-07-02 Caregen Co., Ltd Peptides Having Activities of Insulin Like Growth Factor-1 and their Uses
WO2008086358A1 (en) 2007-01-08 2008-07-17 University Of Southern California Usc Stevens Skin wound healing compositions and methods of use thereof
CN101981055B (zh) 2008-01-31 2016-03-09 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
KR101021197B1 (ko) 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
KR101163171B1 (ko) 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
US8207118B2 (en) * 2009-07-17 2012-06-26 University Of Southern California Skin wound healing compositions and methods of use thereof
NZ599517A (en) * 2009-09-25 2013-07-26 Santen Pharmaceutical Co Ltd Eye drops containing a partial peptide of an insulin-like groth factor I (FGLM) and a tetrapeptide (SSSR)
CN102612373B (zh) * 2009-11-11 2016-03-02 国立大学法人山口大学 消化器官疾病治疗剂
WO2012060832A1 (en) * 2010-11-03 2012-05-10 University Of Southern California Skin wound healing compositions and methods of use thereof
EP3262060B1 (en) * 2015-02-25 2019-12-25 MacKay Memorial Hospital Peptides for use in the prevention and treatment of dry eye
JP6684350B2 (ja) * 2015-12-14 2020-04-22 ツァウ、イェウ−ピンＴＳＡＯ， Ｙｅｏｕ−Ｐｉｎｇ 短い合成ペプチド及びその使用
KR101869783B1 (ko) * 2016-08-17 2018-06-22 (주)진셀팜 미백 활성이 우수한 펩타이드, 및 이의 용도
US10467113B2 (en) * 2017-06-09 2019-11-05 Hewlett Packard Enterprise Development Lp Executing programs through a shared NVM pool
CN112043818A (zh) * 2020-09-16 2020-12-08 温州医科大学附属第一医院 一种用于皮肤创伤的药物及其制备方法和应用
DE112022005006T5 (de) 2021-10-20 2024-08-08 Tataa Biocenter Ab Verfahren und zusammensetzungen zur detektion mutierter nukleinsäuresequenzen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885163A (en) 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
JPS6417489A (en) * 1987-07-13 1989-01-20 Hitachi Ltd Extended substrate
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5104787A (en) 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
JPH0525001A (ja) 1991-07-08 1993-02-02 L Lyndstrom Richard 血清不含有医療用溶液および眼組織の品質を高める方法
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
CA2135306A1 (en) * 1992-05-08 1993-11-25 Bradford A. Jameson Igf-1 analogs
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
JP3191038B2 (ja) * 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
AU7776701A (en) * 2000-08-10 2002-02-25 Santen Pharmaceutical Co Ltd Skin wound healing promoters
JP4096115B2 (ja) * 2000-08-10 2008-06-04 輝夫 西田 皮膚創傷治癒促進剤
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途

Also Published As

Publication number Publication date
KR100967152B1 (ko) 2010-07-05
EP2172474A1 (en) 2010-04-07
CN1263770C (zh) 2006-07-12
US7795222B2 (en) 2010-09-14
AU2002354188A1 (en) 2003-06-17
DK1462455T3 (da) 2013-07-01
EP2172474B1 (en) 2013-04-17
JP4310588B2 (ja) 2009-08-12
JP2008163044A (ja) 2008-07-17
KR20050044630A (ko) 2005-05-12
WO2003048192A1 (fr) 2003-06-12
US20090005317A1 (en) 2009-01-01
CA2469134A1 (en) 2003-06-12
CA2469134C (en) 2013-10-29
EP1462455B1 (en) 2013-04-10
EP1462455A1 (en) 2004-09-29
ES2422081T3 (es) 2013-09-06
CN1599748A (zh) 2005-03-23
KR100993233B1 (ko) 2010-11-10
SI1462455T1 (sl) 2013-09-30
US8183343B2 (en) 2012-05-22
PT1462455E (pt) 2013-07-09
EP1462455A4 (en) 2008-12-31
KR20100002291A (ko) 2010-01-06
TWI305778B (en) 2009-02-01
US20110059897A1 (en) 2011-03-10
US7232881B2 (en) 2007-06-19
US20050009752A1 (en) 2005-01-13
TW200302108A (en) 2003-08-01

Similar Documents

Publication Publication Date Title
CY1114330T1 (el) Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
HK1035336A1 (en) Use of preparations for the application of antiseptic agents and/or agents promoting the healing of wounds to the lower respiratory tract
EA200600750A1 (ru) Трансдермальная фармацевтическая композиция
ECSP055712A (es) Combinación sinérgica de proteínas de seda
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
DE60227389D1 (de) Verwendung von milchserum-apoproteinen bei der prophylaxe oder behandlung von mikrobiellen oder virusinfektionen
CY1106235T1 (el) Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
ES2163805T3 (es) Derivados de acidos benzofurano-acrilicos y su utilizacion como moduladores de los receptores rxrs o rars.
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
DK0658553T3 (da) Hidtil ukendte polycykliske aromatiske forbindelser, farmaceutiske præparater og kosmetiske sammensætninger indeholdende di
AU2003292326A1 (en) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
ITMI932189A1 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
Menkes Initial evaluation and management of orthopedic injuries
NO980375L (no) Humant MP52 Arg protein
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
WO2012046922A1 (en) Novel use of antimicrobial peptides in regeneration of skin cells
AR012702A1 (es) Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
ATE446759T1 (de) Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
WO2022098944A1 (en) Composition for increasing skin thickness
MXJL03000041A (es) Sistema para antisepsia en cirugia ocular.
RU93031950A (ru) Препарат для лечения ран